MeiraGTx/$MGTX
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Ticker
$MGTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
372
ISIN
KYG596651029
Website
MeiraGTx Metrics
BasicAdvanced
$693M
-
-$2.27
1.31
-
Price and volume
Market cap
$693M
Beta
1.31
52-week high
$8.75
52-week low
$3.85
Average daily volume
519K
Financial strength
Current ratio
1.525
Quick ratio
1.37
Long term debt to equity
234.391
Total debt to equity
244.352
Interest coverage (TTM)
-12.17%
Profitability
EBITDA (TTM)
-146.402
Gross margin (TTM)
27.06%
Net profit margin (TTM)
-484.90%
Operating margin (TTM)
-460.87%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-37.28%
Return on equity (TTM)
-216.14%
Valuation
Price to revenue (TTM)
18.376
Price to book
20.68
Price to tangible book (TTM)
21.18
Price to free cash flow (TTM)
-5.787
Free cash flow yield (TTM)
-17.28%
Free cash flow per share (TTM)
-148.94%
Growth
Revenue change (TTM)
203.23%
Earnings per share change (TTM)
84.70%
3-year revenue growth (CAGR)
-3.78%
3-year earnings per share growth (CAGR)
5.00%
What the Analysts think about MeiraGTx
Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
Bulls say / Bears say
MeiraGTx's revenue increased by 137.42% in 2024, reaching $33.28 million, indicating strong growth potential. (stockanalysis.com)
The company secured a $200 million upfront payment and additional committed capital of $230 million through a joint venture with Hologen AI, enhancing its financial position. (ainvest.com)
MeiraGTx received Regenerative Medicine Advanced Therapy (RMAT) designation for its Parkinson’s disease program, potentially expediting regulatory approval. (ainvest.com)
The company's net loss widened to $147.8 million in 2024, up from $84.0 million in 2023, raising concerns about financial sustainability. (meiragtx.com)
MeiraGTx's Altman Z-score of -2.10 places it in the distress zone, indicating a higher risk of bankruptcy within the next two years. (gurufocus.com)
The company reported a 95.6% increase in net loss for Q1 2025, missing revenue expectations by 76.85%, which may affect investor confidence. (ainvest.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
MeiraGTx Financial Performance
Revenues and expenses
MeiraGTx Earnings Performance
Company profitability
MeiraGTx News
AllArticlesVideos
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
GlobeNewsWire·2 months ago
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
GlobeNewsWire·2 months ago
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MeiraGTx stock?
MeiraGTx (MGTX) has a market cap of $693M as of July 11, 2025.
What is the P/E ratio for MeiraGTx stock?
The price to earnings (P/E) ratio for MeiraGTx (MGTX) stock is 0 as of July 11, 2025.
Does MeiraGTx stock pay dividends?
No, MeiraGTx (MGTX) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next MeiraGTx dividend payment date?
MeiraGTx (MGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MeiraGTx?
MeiraGTx (MGTX) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.